Document is current
Any future updates will be listed below
-
Authors
Reilly, John P. https://orcid.org/0000-0003-3937-5320
Zhao, Zhiguo
Shashaty, Michael G. S.
Koyama, Tatsuki
Jones, Tiffanie K.
Anderson, Brian J.
Ittner, Caroline A.
Dunn, Thomas
Miano, Todd A.
Oniyide, Oluwatosin
Balmes, John R.
Matthay, Michael A.
Calfee, Carolyn S.
Christie, Jason D.
Meyer, Nuala J.
Ware, Lorraine B.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01 HL155159, K23 HL125723, K24 HL155804, R35 HL161196, K24 HL103836, R01 HL158906, R35 HL140026)
NIH Office of the Director (S10 OD025172)
- License Information
-
More Information
Article History
Received: 6 April 2023
Accepted: 20 June 2023
First Online: 20 July 2023
Declarations
:
: LBW reports consulting fees from Akebia, Santhera, Global Blood Therapeutics, and Boerhinger Ingelheim and research contract support (paid to institution) from Genentech, Boehringer Ingelheim, and CSL Behring all unrelated to the topic of this article. NJM reports consulting fees from Endpoint Health, Inc and research contract support to her institution from Quantum Leap Healthcare Collaborative and Biomarck, Inc. CSC reports consulting fees from Vasomune, Gen1e Life Sciences, Cellenkos, NGMBio, and Janssen, and research support to her institution from Roche-Genentech and Quantum Leap Healthcare Collaborative, all unrelated to this article. MAM reports research grant funding from Roche-Genentec and Quatum Therapeutics, and consultation for Novartis, Citius Pharmaceuticals, Johnson and Johnson, Gilead Pharmaceuticals, and ElifeScience.
